Response of the clinically uninvolved skin of psoriatic patients to repeated tape stripping during cyclosporin A treatment.
It is well established that cyclosporin A (CyA), a widely used immunosuppressant in human organ transplantation, is an effective drug in the treatment of psoriasis. Although it has been postulated that the effect of CyA in psoriasis is mediated through antilymphocyte activity, there is also evidence suggesting that CyA exerts a direct cytostatic effect on epidermal keratinocytes, but results of studies relating to the latter have been contradictory. Using immunohistochemical methods we investigated the influence of systemic CyA on proliferation and differentiation in the tape-stripped uninvolved skin of psoriatic patients, a model which provides the opportunity of studying epidermal regeneration in the absence of a significant accumulation of T lymphocytes. We addressed the question of whether CyA (3-5 mg/kg/day) modulates epidermal proliferation and differentiation following standardized injury in uninvolved skin of psoriatic patients. Ten patients with severe psoriasis participated in this study. The dosages of CyA were sufficient to induce a marked and statistically significant improvement (PASI, week 0, 20.5 +/- 4.4; PASI, week 16, 4.3 +/- 0.6). Before CyA treatment, and during week 16 of treatment, Sellotape stripping was carried out on a 2-cm2 area of the uninvolved skin of psoriatic patients. After 48 h punch biopsies were taken. Immunohistochemical assessment of recruitment of cycling cells (Ki-67), filaggrin, involucrin, T lymphocytes and tenascin, was carried out. We did not find any significant alteration during the treatment period in the tape-stripped uninvolved skin of psoriatic patients. We conclude that epidermal hyperproliferation and abnormal keratinization are not modulated directly by CyA at therapeutic doses in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
Gerritsen
M J
MJ
Department of Dermatology, University Hospital Nijmegen, The Netherlands.
Rulo
H F
HF
Arnold
W P
WP
Van de Kerkhof
P C
PC
D015816:Cell Adhesion Molecules, Neuronal / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D016572:Cyclosporine / Q000627:therapeutic use*; D004817:Epidermis / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D000091344:Filaggrin Proteins; D006801:Humans; D007150:Immunohistochemistry; D007381:Intermediate Filament Proteins / Q000378:metabolism; D015603:Keratinocytes / Q000473:pathology*; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins / Q000276:immunology; D009687:Nuclear Proteins / Q000276:immunology; D011498:Protein Precursors / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D013601:T-Lymphocytes; D019063:Tenascin
D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011498:Protein Precursors; D019063:Tenascin; C032253:involucrin; D016572:Cyclosporine